Colonic Diseases, Functional: Clinical Trials

60 trials for Colonic Diseases, Functional, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

39 completed, 17 unknown, 3 terminated, 1 not yet recruiting. 60 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 460Completed 39, Unknown 17, Terminated 3, Not yet recruiting 1

Follow Colonic Diseases, Functional: new trials by email Literature Review of Colonic Diseases, Functional trials Research Report on Colonic Diseases, Functional

Trials (filtered) newest first · largest first

All 60 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
"Efficacy and Safety of Linaclotide in Chronic Constipation"
Linaclotide 72 micrograms, Linaclotide 145 micrograms, Placebo - Chronic Idiopathic Constipation, Irritable Bowel Syndrome (IBS-C)
Phase 4Not yet recruitingMd Mehedi Shahriar902026-02-202026-02-25
Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome
Skal Pro, Placebo - Irritable Bowel Syndrome, Gastrointestinal Diseases
Phase 4CompletedEP Plus Group Sdn Bhd572024-10-172026-09-11
The Effects of Probiotics, Lactobacillus GG, in the Treatment of Abdominal Pain in Children With Functional Abdominal Pain Disorders
LGG, Placebo - Functional Abdominal Pain Syndrome
Phase 4UnknownPrince of Songkla University542024-03-212024-03-18
Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation
Tenapanor - IBS, IBS - Irritable Bowel Syndrome
Phase 4CompletedKyle Staller, MD, MPH362024-02-062026-03-12
Efficacy and Safety of Dietary Supplementation of Diamine Oxidase to Improve Symptoms in Patients With IBS
DAO supplement, Placebo - Irritable Bowel Syndrome (IBS)
Phase 4UnknownNanjing First Hospital, Nanjing Medical University1502023-11-012023-11-18
To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea
Rifaximin 550 MG, Mebeverine 135 MG, Psyllium Husk - Irritable Bowel Syndrome With Diarrhea
Phase 4CompletedBahria University1622023-01-032023-07-27
Efficacy and Safety of a Probiotic Formulation in Adults With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Probiotic formulation, Placebo - IBS - Irritable Bowel Syndrome
Phase 4UnknownLallemand Health Solutions1622022-08-112024-02-20
Colonoscopic Probiotics Infusion for Functional Gastrointestinal Disease
Live Combined Bifidobacterium and Lactobacillus, Normal saline, Basic treatment - Functional Constipation, Irritable Bowel Syndrome
Phase 4UnknownFirst Affiliated Hospital Xi'an Jiaotong University1602022-07-042022-08-04
Neostigmine Route for Acute Colonic Pseudo Obstruction
Neostigmine - Ogilvie Syndrome
Phase 4UnknownUniversity of Southern California902022-02-042023-08-25
Postinfectious Irritable Bowel Syndrome and Gelsectan
(Gelsectan, Devintec Sagl) - Irritable Bowel Syndrome
Phase 4CompletedEvangelismos Hospital2752021-09-012024-02-28
Rifaximin Therapy vs Low FODMAP Diet In IBS
Rifaximin, Low FODMAP diet - Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Phase 4UnknownUniversity of Malaya1002021-04-222023-05-16
Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders
Linaclotide, Lactulose, Omeprazol - Functional Dyspepsia, Constipation-predominant Irritable Bowel Syndrome
Phase 4UnknownRenJi Hospital782021-01-012021-12-13
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
Iberogast® and Iberogast® N - Irritable Bowel Syndrome, Functional Dyspepsia
Phase 4CompletedHospital Vall d'Hebron682020-09-032023-09-22
Helicobacter Pylori Eradication and Irritable Bowel Syndrome: A Prospective Study
Triple therapy for H.pylori - Irritable Bowel Syndrome
Phase 4UnknownAssiut University1002020-08-102020-08-14
Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D
Rifaximin, Probiotic Formula, Placebo oral tablet - IBS - Irritable Bowel Syndrome, Gut Microbiota
Phase 4UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine2402020-05-102020-07-28
Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea
Rifaximin, Glucose and lactulose hydrogen breath testing - Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
Phase 4CompletedUniversity of Michigan1482020-01-092026-01-12
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
I31 probiotic, I31 probiotic combined to Alverine/Simethicone, Placebo - Irritable Bowel Syndrome
Phase 4CompletedHospital Juarez de Mexico552018-09-032020-01-23
The DOMINO Trial: Diet Or Medication in Irritable Bowel syNdrOme
IBS Diet, Otilonium Bromide - Irritable Bowel Syndrome
Phase 4CompletedUniversitaire Ziekenhuizen KU Leuven4722018-07-262020-11-17
A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
Rifaximin 550 MG, Low FODMAP Diet - Irritable Bowel Syndrome
Phase 4CompletedUniversity of Michigan742018-02-132025-04-27
Efficacy and Safety of Saccharomyces Boulardii in the Treatment of Small Intestinal Bacterial Overgrowth
Saccharomyces Boulardii 250 MG, Dietary advice following a low fermentation diet - Irritable Bowel Syndrome
Phase 4CompletedCentro de Educación Medica e Investigaciones Clínicas Norberto Quirno712017-02-012020-11-13

Showing 20 of 60. Sign in to see all of them.

Narrower conditions

Irritable Bowel Syndrome (58)  ·  Diarrhea (6)  ·  Abdominal Pain (4)  ·  Colonic Diseases (3)  ·  Colitis, Ulcerative (2)  ·  Constipation (2)  ·  Depressive Disorder, Major (2)  ·  Digestive System Diseases (2)  ·  Flatulence (2)  ·  Gastrointestinal Diseases (2)  ·  Colonic Pseudo-Obstruction (1)  ·  Cystitis, Interstitial (1)  ·  Depression (1)  ·  Disease (1)

Broader conditions

Intestinal Diseases (59)  ·  Digestive System Diseases (58)  ·  Gastrointestinal Diseases (58)  ·  Colonic Diseases (57)  ·  Pathological Conditions, Signs and Symptoms (13)  ·  Signs and Symptoms (12)  ·  Signs and Symptoms, Digestive (11)  ·  Neurologic Manifestations (5)  ·  Mental Disorders (4)  ·  Pain (4)  ·  Anxiety Disorders (2)  ·  Colitis (2)  ·  Depressive Disorder (2)  ·  Gastroenteritis (2)

Interventions

Rifaximin (5)  ·  Duloxetine Hydrochloride (3)  ·  FODMAP Diet (3)  ·  Probiotics (3)  ·  Simethicone (3)  ·  Escitalopram (2)  ·  Lacteol (2)  ·  Sugars (2)  ·  alverine (2)  ·  ebastine (2)  ·  mebeverine (2)  ·  octylonium (2)  ·  ramosetron (2)  ·  (1-6)-alpha-glucomannan (1)  ·  Amitriptyline (1)

Sponsors

Astellas Pharma Inc (2)  ·  KU Leuven (2)  ·  Laboratoires Mayoly Spindler (2)  ·  Shandong University (2)  ·  University of Michigan (2)  ·  Aga Khan University (1)  ·  American Academy of Family Physicians (1)  ·  Asian Institute of Gastroenterology, India (1)  ·  Assiut University (1)  ·  Azienda Policlinico Umberto I (1)  ·  Bahria University (1)  ·  Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1)  ·  Bukwang Pharmaceutical (1)  ·  Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno (1)  ·  Chinese University of Hong Kong (1)

Countries

United States (13)  ·  China (6)  ·  Italy (4)  ·  Belgium (3)  ·  Pakistan (3)  ·  United Kingdom (3)  ·  Japan (2)  ·  Malaysia (2)  ·  Netherlands (2)  ·  Poland (2)  ·  South Korea (2)  ·  Spain (2)  ·  Argentina (1)  ·  Bangladesh (1)  ·  Greece (1)

Top investigators

Guy Boeckxstaens, M.D. (2)  ·  Abdullah Aljahdali, MD (1)  ·  Abed Allehibi, Dr (1)  ·  Alicia J Kaplan, MD (1)  ·  Allen Lee, MD (1)  ·  Andrea Horvath, MD (1)  ·  Anna H Lyra, PhD (1)  ·  Arthur C Ouwehand, PhD (1)  ·  Ashton Harper, MRCS (1)  ·  Ashwin A Patkar, M.D. (1)  ·  Brian P Brennan, MD (1)  ·  Cheryl Stevenson, M.Sc (1)  ·  Dr. Nageshwar Reddy, DM (1)  ·  Dr. Nitesh Pratap, DM (1)

Results publications

PMID 19158975, PMID 19548294, PMID 21087463, PMID 23602047, PMID 23716985, PMID 23980534, PMID 24063420, PMID 24147869, PMID 26396720, PMID 26752109, PMID 27306945, PMID 27490103, PMID 28293280, PMID 28331539, PMID 29801486, PMID 31677711, PMID 33038815, PMID 35483886, PMID 38191268, PMID 39086991, PMID 40079184, PMID 41098003, PMID 41436948, PMID 42025708, PMID 42609157, PMID 42663160

NIH funding

2009 (1), K23DK124567 (1), UL1RR024150 (1)